All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub
Brought to you by Scientific Education Support

The Lupus Hub is an independent medical education platform, sponsored by Autolus, Biogen and Biogen MA, Inc. and UCB. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

SLEuro Congress 2022

Share:

Oct 11, 2022

X post image

20 May 2023

Have you watched this yet?

#lupus2022 |🎥 During the 13th European Lupus Meeting, the Lupus Hub was pleased to speak to Jill Buyon. We asked, What do HCPs need to know about neonatal lupus?

Watch the full video here 👇
https://t.co/Zefx5EHrTz

View on 

X post image

3 Apr 2023

#lupus2022 |🎥 During the 13th European Lupus Meeting, the Lupus Hub was pleased to speak to Jill Buyon. We asked, What do HCPs need to know about neonatal lupus?

Watch the full video here 👇
https://t.co/N3YDIYnPzi

View on 

X post image

12 Dec 2022

#lupus2022 | 🎥 During the 13th European Lupus Meeting, the Lupus Hub was pleased to speak to Jill Buyon. We asked, What do HCPs need to know about neonatal lupus?

Watch the full video here 👇
https://t.co/Zefx5EHrTz

View on 

X post image

10 Oct 2022

Thank you for following our live updates from #lupus2022!

Stay tuned and follow us for post-congress insights and updates. 📲

#lupus #autoimmunedisease
@SLEuroSociety

View on 

X post image

8 Oct 2022

How do our results compare to in the session at #LUPUS2022?

Initially the vote was ~70% thought #sle should be classified as several disease entities.

However after the debate, the room was pretty evenly split.

Share your thoughts on this with us in the comments.

View on 

X post image

7 Oct 2022

Congress #lupus2022 | @YannNgyn @HopitalCochin @UP_Medecine is speaking about severe non-adherence to HCQ & the sequelae. Non-adherence is associated with increased incidence of flares, increased damage in years 1-3 after diagnosis and 5 year mortality

View on 

X post image

7 Oct 2022

Congress #lupus2022 | Jane Salmon @WeillCornell talks about whether we can predict & prevent pregnancy complications in pts with lupus & APS. She concludes that yes we can predict complications but whether we can prevent them is unclear. Must wait for results of the IMPACT study

View on 

X post image

7 Oct 2022

Congress #lupus2022 | In this debate session @ronfvv is arguing that #SLE is several diseases as opposed to one, while Martin Aringer presents the counter position.

📢 Have your say! Is SLE one or several disease entities?

View on 

X post image

7 Oct 2022

Congress #LUPUS2022 | How is patient centred care best organised by the lupus team is the topic for this all female fishbowl discussion. Specialists talking to each other about individual pts & learning from each other was highlighted. Having a centre on 1 site was also favoured

View on 

X post image

7 Oct 2022

Congress #lupus2022 | @lauraandreoli80 @unibs_official discusses renal outcomes in pts treated with belimumab in the phase 3 BLISS-LN trial. While she highlighted the small sample size, a trend was seen in favour of BEL vs PBO at Week 104 for complete renal response rate & uPCR

View on 

X post image

7 Oct 2022

RT @pekor002: ⁦@lauraandreoli80⁩ presenting a BLISS-LN subanalysis from European patients in the #epostersession at #lupus2022. https://t.c…

View on 

X post image

7 Oct 2022

Congress #lupus2022 | @gomezg_alvaro @karolinskainst investigates belimumab and antimalarial agents efficacy in preventing renal flares in #SLE N=3225 of which 192 had renal flares. Use of antimalarial agents and low-dose BEL was associated with lower risk of renal flares p=0.005

View on 

X post image

7 Oct 2022

Congress #lupus2022 | Richard Furie @NorthwellHealth describes extra-renal outcomes following belimumab treatment in the BLISS-LN trial. N=448. At week 104, BEL-treated>PBO-treated pts improved from baseline in the immunologic, CV / respiratory & vascular SLEDAIS2K domains

View on 

X post image

7 Oct 2022

Congress #lupus2022 | @IoannisParodis @karolinskainst presents a poster on PK modeling of belimumab exploring IV & SC dosing. PK simulations predicted that the SC dose with 4-wk loading (400 mg QW to d21) would achieve an average BEL exposure similar to the IV regimen

View on 

X post image

7 Oct 2022

RT @G_O_Daniel: This is why #Lupus2022 is such a great meeting. All things #Lupus and colleagues and experts from all specialties sharing t…

View on 

X post image

7 Oct 2022

Congress #lupus2022 | Valentina Varriano @Unicatt talks about the IL-17/ IL-23 axis in pts with LN. N=91. Interstitial inflammatory infiltrate & APL+ were the strongest predictors of worse renal outcome. Also, a higher IL-23 serum level was a negative prognostic factor.

View on 

X post image

7 Oct 2022

Congress #lupus2022 | @ykoteng_LUMC @LUMC_Leiden discusses voclosporin with MMF + low dose steroids from the AURORA-2 study N=216. Significant reductions in proteinuria were achieved in the absence of traditional high-dose steroids. No new safety signals observed.

View on 

X post image

7 Oct 2022

Congress #lupus2022 | Frédéric Houssiau @UCLouvain_be presents an update on treatments for #lupusnephritis. He highlights belimumab, voclosporin and anifrolumab. At the end states in his opinion that a gain of 10-20% CRR will translate into less CKD/ ESKD

View on 

X post image

7 Oct 2022

The @Lupus_hub is sharing the latest updates from #LUPUS2022.

Oral sessions covered today:

Nephritis

Pregnancy and hormones

Steroids/ HCQ and DMARDS

Poster session:
Lupus nephritis

#lupus #autoimmunedisease

View on 

X post image

6 Oct 2022

Great to meet Betty Diamond at #LUPUS2022 before her excellent talk on neuropsychiatric SLE 🤩 https://t.co/FkTYshMskC

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | @micaela_fredi Civil Hospital of Brescia presents a session on the difference between physician and patient perceptions. N=106. Even in pts in remission >20% showed discordance between phGA & PGA. May be due to presence of depression and/ anxiety

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | Jens Humrich @UKSH_KI_HL discusses a phase II trial of low dose IL-2 in pts with #sle. N=100. After excluding 2 study sites that achieved 100% SRI4 in placebo group, a difference was seen: ILT-101 (83.3%) vs placebo (51.7%) for the SRI4 RR (p=0.0168)

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | Ronald van Vollenhoven @ronfvv @UvA_Amsterdam describes the results of a phase II study of deucravacitinib. N=363. A significantly increased % of pts in the DEU 3mg BID or 6mg BID achieved SRI4 response. AE rates were similar between DEU & PBO groups

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | Falk Hiepe @ChariteBerlin is talking about new treatments for #sle including daratumumab and the anti-CD19 CAR T cells that are one of the hot topics of the meeting

View on 

X post image

6 Oct 2022

RT @cristianasieiro: #LUPUS2022
Pf. S Khampuis: Clinical differences between juvenile and adult onset lupus
☑️Higher severity of the diseas…

View on 

X post image

6 Oct 2022

RT @cristianasieiro: #LUPUS2022
Prof. Arnaud @Lupusreference gives a great presentation on male patients with SLE.
☑️SLE more common in fem…

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | Elin Lundqvist @UU_University talks about HLA-DRB1*03:01 STAT4 & risk of LN. Prev class III/IV LN with 3-4 risk variants =30% vs 16% in pts with 0-2, p=0.001. Decreased time of onset of class III/IV LN was seen in pts with 3-4 risk alleles vs 0-2

View on 

X post image

6 Oct 2022

Congress #SLEuro #LUPUS2022 | Marta Alarcon-Riqelme @genyo_pts discusses how genetics and genomics can be used to stratify patients with #SLE. While she states molecular patterns can be used to predict flares, neutrophils are key and they must drop if no flare within 3 months

View on 

X post image

6 Oct 2022

Our coverage from #Lupus2022 starts today!

The @Lupus_hub will be covering the following sessions today:

Genetics in SLE

Old and new drugs in SLE

Immune system in SLE

And clinical challenges

#lupus #autoimmunedisease #SLEuro

View on 

X post image

5 Oct 2022

The @lupus_hub will be attending the 13th European Lupus Meeting #lupus2022 in person and providing live updates!

🗓 Oct 5–8
📍 Stockholm, SE

80+ speakers will be covering topics such as disease mechanisms, clinical challenges, and drug updates in SLE.

@SLEuroSociety

#lupus

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

SLEuro 2022European Lupus Society

Newsletter

Subscribe to get the best content delivered to your inbox